LKB1 Loss Assessed by Immunohistochemistry as a Prognostic Marker to First-Line Therapy in Advanced Non-Small-Cell Lung Cancer

LKB1 Loss Assessed by Immunohistochemistry as a Prognostic Marker to First-Line Therapy in Advanced Non-Small-Cell Lung Cancer

(1) Background: Liver kinase B1 (LKB1) is a tumor suppressor gene involved in cell growth and metabolism. However, its alterations are not routinely assessed for guiding therapy in clinical practice. We assessed LKB1 expression by immunohistochemistry as a potential biomarker. (2) Methods: This bice...

Full description

Bibliographic Details
Main Authors: Alejandro Avilés-Salas, Diego A. Díaz-García, Luis Lara-Mejía, Andrés F. Cardona, Mario Orozco-Morales, Rodrigo Catalán, Norma Y. Hernández-Pedro, Eduardo Rios-Garcia, Maritza Ramos-Ramírez, Oscar Arrieta
Format: Article
Language:English
Published: MDPI AG 2022-12-01
Series:Current Oncology
Subjects:
lung cancer
advanced NSCLC
STK11
prognostic biomarker
immunohistochemistry
Online Access:https://www.mdpi.com/1718-7729/30/1/27

Internet

https://www.mdpi.com/1718-7729/30/1/27

Similar Items